Published in Med Sci Monit on July 02, 2015
Current status of lymph node micrometastasis in gastric cancer. Oncotarget (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (2012) 6.83
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol (2011) 6.18
A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg (2010) 2.27
Prognostic factors and recurrence pattern in node-negative advanced gastric cancer. Eur J Surg Oncol (2012) 2.05
Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol (2002) 1.40
Biologic predictors of survival in node-negative gastric cancer. Ann Surg (2003) 1.37
Effect of lymph node number on survival of patients with lymph node-negative gastric cancer according to the 7th edition UICC TNM system. PLoS One (2012) 1.20
Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer (2005) 1.20
Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. Int J Clin Exp Pathol (2013) 1.13
Clinicopathologic study of node-negative advanced gastric cancer and analysis of factors predicting its recurrence and prognosis. Am J Surg (2012) 1.13
Prognostic indicators in node-negative advanced gastric cancer patients. J Surg Oncol (2010) 1.11
Prognostic factors in patients with node-negative gastric carcinoma: a comparison with node-positive gastric carcinoma. World J Gastroenterol (2006) 1.10
Prognostic indicators for survival after curative resection for patients with carcinoma of the stomach. Dig Dis Sci (1997) 1.05
Clinicopathologic characteristics and outcome indicators in node-negative gastric cancer. J Surg Oncol (2000) 1.02
Prognostic impact of lymphatic invasion in patients with node-negative gastric cancer. J Surg Oncol (2009) 1.01
Factors Associated With Recurrence and Survival in Lymph Node-negative Gastric Adenocarcinoma: A 7-Institution Study of the US Gastric Cancer Collaborative. Ann Surg (2015) 0.99
Survival predictors in patients with node-negative gastric carcinoma. J Gastroenterol Hepatol (2007) 0.99
Impact on survival of the number of lymph nodes removed in patients with node-negative gastric cancer submitted to extended lymph node dissection. Eur J Surg Oncol (2011) 0.99
Adverse prognosis of clustered-cell versus single-cell micrometastases in pN0 early gastric cancer. J Surg Oncol (2011) 0.98
Prognostic analysis in node-negative gastric cancer patients in China. Tumour Biol (2010) 0.95
Prognostic significance of lymphovascular invasion in node-negative gastric cancer. World J Surg (2015) 0.95
Prognostic factors on overall survival in lymph node negative gastric cancer patients who underwent curative resection. J Gastric Cancer (2012) 0.94
Comparison of disease-specific survival in the United States and Korea after resection for early-stage node-negative gastric carcinoma. J Surg Oncol (2012) 0.93
Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer. Int J Cancer (2011) 0.92
Prognosis of gastric cancer patients with node-negative metastasis following curative resection: outcomes of the survival and recurrence. Can J Gastroenterol (2008) 0.90
Prognostic value of number of examined lymph nodes in patients with node-negative gastric cancer. World J Gastroenterol (2014) 0.88
Prognostic factors in patients with node-negative gastric cancer: a single center experience from China. J Gastrointest Surg (2012) 0.86
Prognostic impact of venous invasion in stage IB node-negative gastric cancer. Gastric Cancer (2014) 0.85
Prognostic factors in patients with node-negative gastric cancer: an Indian experience. World J Surg Oncol (2011) 0.83
Efficacy of prophylactic extended lymphadenectomy with gastrectomy for patients with node-negative advanced gastric carcinoma. Hepatogastroenterology (2008) 0.83
Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer. J Surg Oncol (2011) 0.82
Does tumor size improve the accuracy of prognostic predictions in node-negative gastric cancer (pT1-4aN0M0 stage)? PLoS One (2014) 0.82
Lymphangiogenic and angiogenic microvessel density in chinese patients with gastric carcinoma: correlation with clinicopathologic parameters and prognosis. Asian Pac J Cancer Prev (2013) 0.80
Prognostic factors for patients with node-negative gastric cancer: Can extended lymph node dissection have a survival benefit? J Surg Oncol (2006) 0.79
Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases. World J Gastroenterol (2013) 0.79
Predictive factors for survival and recurrence rate in patients with node-negative gastric cancer--a European single-centre experience. Langenbecks Arch Surg (2014) 0.79
Therapeutic strategy for patients with pN0 gastric carcinoma. J Surg Oncol (2006) 0.77
Do patients with pN0 gastric cancer benefit from prophylactic extended lymphadenectomy? Surg Oncol (2011) 0.77